John Peter McLaughlin is Director at PDL BIOPHARMA, INC. (PDLI). They have made 1 open-market trade across 1 company since 2020, most recently 2023-05-25.
CIK 0001277967
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PDLI | SELL | 2020-12-21 | 2020-12-22 | $2.61 | $1.6M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.